Li-Dan Xu, Chong-Yang Ma, Zhi-Yao Zhu, Tian An
Euonymus alatus: (EA), a traditional Chinese botanical drug documented in the Shennong Ben Cao Jing, has been investigated for its potential anti-diabetic effects. This review systematically examines the phytochemistry, pharmacokinetics, and anti-diabetic mechanisms of this botanical drug. Over 230 metabolites, including flavonoids, triterpenoids, and lignans, have been identified from EA. Pharmacokinetic studies remain limited; computational predictions suggest that some metabolites may exhibit oral bioavailability, but classical pharmacokinetic parameters have not been experimentally determined for any EA metabolite. Mechanistic studies demonstrate that EA exerts anti-diabetic effects through multiple experimentally validated pathways: (i) inhibiting alpha-glucosidase activity to delay intestinal glucose absorption; (ii) activating the peroxisome proliferator-activated receptor gamma and phosphatidylinositol 3-kinase/protein kinase B signaling pathways to ameliorate insulin resistance; (iii) modulating gut microbiota composition and increasing short-chain fatty acid production; (iv) suppressing the advanced glycation end products-receptor for advanced glycation end products axis along with the nuclear factor kappa B and mitogen-activated protein kinase inflammatory pathways to alleviate oxidative stress and inflammatory responses; and (v) regulating diacylglycerol acyltransferase activity to improve lipid metabolism. Preclinical studies indicate that EA reduces blood glucose and improves markers of diabetic nephropathy and retinopathy. Clinical studies of EA-containing formulations report reductions in fasting blood glucose and urinary protein. However, the clinical evidence remains limited by small sample sizes, lack of rigorous controls, and multi-botanical drug compositions that preclude attribution of effects to individual components. This review provides a critical synthesis of current evidence and identifies priorities for future investigation.